

<b>OMB APPROVAL</b>	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>VAN VLASSELAER PETER</u>  (Last) (First) (Middle) C/O ARMO BIOSCIENCES, INC. 575 CHESAPEAKE DRIVE  (Street) REDWOOD CA 94063 CITY  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/25/2018	3. Issuer Name and Ticker or Trading Symbol <u>ARMO BioSciences, Inc. [ ARMO ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;"><u>President and CEO</u></p>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	809,865	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (right to buy)	(1)	07/20/2024	Common Stock	190,641	1.3186	D
Stock Option (right to buy)	(2)	07/20/2024	Common Stock	220,513	1.3186	D
Stock Option (right to buy)	(3)	01/19/2026	Common Stock	398,206	3.2965	D
Stock Option (right to buy)	(4)	12/12/2027	Common Stock	216,168	6.9698	D

**Explanation of Responses:**

- The option is exercisable in 48 equal monthly installments after May 16, 2014 provided the reporting person remains in continuous service on each vesting date; the option may also be exercised early subject to Issuer's right of repurchase.
- The option is exercisable in 48 equal monthly installments after February 17, 2015 provided the reporting person remains in continuous service on each vesting date; the option may also be exercised early subject to Issuer's right of repurchase.
- The option is exercisable in 48 equal monthly installments after November 5, 2015 provided the reporting person remains in continuous service on each vesting date; the option may also be exercised early subject to Issuer's right of repurchase.
- The option is exercisable in 48 equal monthly installments after December 13, 2017 provided the reporting person remains in continuous service on each vesting date; the option may also be exercised early subject to Issuer's right of repurchase.

**Remarks:**

/s/ Scott S. Paraker, Attorney-in-Fact 01/25/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of ARMO BioSciences, Inc., a Delaware corporation (the "Company") hereby constitutes and appoints each of the persons listed on Exhibit A attached hereto, the undersigned's true and lawful attorney-in-fact to:

(1) complete and execute Form ID, "Update Passphrase Confirmation" form and Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determined to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

(2) do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12 day of January, 2018.

/s/ Peter Van Vlassalaer

-----  
Peter Van Vlassalaer

EXHIBIT A

Marcia Hatch  
Heidi Mayon  
Colin Conklin  
Sogoal Salari  
Elaine Sylvester  
Scott Paraker  
Herb Cross  
Clinton Musil